Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01937130 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
A Phase 2 study, sponsored by Conatus Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01937130 is a Phase 2 study that was terminated before completion, run by Conatus Pharmaceuticals. The registered enrollment target is 23 participants.
The verdict
NCT01937130, a Phase 2 study, was terminated before completion, sponsored by Conatus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The study will evaluate the pharmacokinetics, pharmacodynamics, safety and preliminary efficacy of IDN-6556 in subjects with cirrhosis of the liver who are hospitalized for more than 24 hours due to acute deterioration of liver function.
Interventions
- OTHER Placebo
- DRUG IDN-6556
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-09 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01937130
The ClinicalTrials.gov registry entry for NCT01937130 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Conatus Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01937130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01937130 about?
NCT01937130 is a clinical study titled "Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF". The study will evaluate the pharmacokinetics, pharmacodynamics, safety and preliminary efficacy of IDN-6556 in subjects with cirrhosis of the liver who are hospitalized for more than 24 hours due to acute deterioration of liver function.
What is the current status of trial NCT01937130?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2013-09. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01937130?
The interventions under investigation include: Placebo (OTHER), IDN-6556 (DRUG).
Who is sponsoring clinical trial NCT01937130?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.